Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
July 7, 2022
July 7, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from AbbVie.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward allergists, clinical immunologists, and specialty nurse practitioners, and physician assistants.
This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on opportunities for improved diagnosis and management of patients with moderate to severe atopic dermatitis (AD). The engaging format of this program includes video commentary from expert thought leaders along with depictions of sample patient interactions.
Upon completion of this activity, participants should be better able to:
- Outline the burden of moderate-to-severe disease in patients with AD
- Apply current guidelines for the management of patients with moderate-to-severe AD
- Assess clinical trial data for new and emerging therapies for the management of moderate-to-severe AD
- Develop individualized management plans using shared decision-making principles for patients with AD
Jonathan I. Silverberg, MD, PhD, MPH, FAAD
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Peck Y. Ong, MD
Associate Professor of Clinical Pediatrics
Division of Clinical Immunology and Allergy
Children’s Hospital Los Angeles
University of Southern California
Los Angeles, CA
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Jonathan I. Silverberg, MD, PhD, MPH, FAAD
- Grant/Research Support: Galderma, Pfizer
- Consultant: AbbVie, Afyx Therapeutics, AOBiome, Arena, Asana, Aslan, BiomX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, DermTech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Luna, Menio
- Speakers Bureau: AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme.
- Peck Y. Ong, MD
- Grant/Research Support: Regeneron, Sanofi Genzyme, Leo Pharma, Incyte
- Consultant: Sanofi Genzyme, Janssen, Incyte, AbbVie
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.